PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28792166-0 2017 Evaluation of Effect of Ascorbic Acid on Ferritin and Erythropoietin Resistance in Patients of Chronic Kidney Disease. Ascorbic Acid 24-37 erythropoietin Homo sapiens 54-68 1336813-1 1992 The effect of erythropoietin (Ep), a glycoprotein hormone, has been studied on lipid peroxidation induced by Cu2+ and ascorbate in vitro, Mg2+ ATPase activity and spectrin of RBC membrane. Ascorbic Acid 118-127 erythropoietin Homo sapiens 14-28 8524494-0 1995 Resistance to erythropoietin in iron-overloaded haemodialysis patients can be overcome by ascorbic acid administration. Ascorbic Acid 90-103 erythropoietin Homo sapiens 14-28 8524494-8 1995 Also, ascorbate supplementation was continued after the study in two patients and allowed the erythropoietin doses to be decreased, 8 and 11 weeks, respectively, after the start of the trial. Ascorbic Acid 6-15 erythropoietin Homo sapiens 94-108 8524494-10 1995 We conclude that ascorbate supplementation may circumvent resistance to erythropoietin that sometimes occurs in iron-overloaded patients, in particular, in the setting of "functional iron deficiency". Ascorbic Acid 17-26 erythropoietin Homo sapiens 72-86 34376935-2 2021 This study hypothesis was that in patients undergoing hemodialysis (HD), administration of intravenous (IV) ascorbic acid (AA) exerts a good effect on the management of anemia, either by increasing the mobilization of iron from tissue stores or acting as an antioxidant to overcome the inflammatory block and increase the erythropoietin sensitivity. Ascorbic Acid 108-121 erythropoietin Homo sapiens 322-336 28792166-1 2017 OBJECTIVE: This study was planned to evaluate the effect of short term intravenous ascorbic acid on reducing ferritin and erythropoietin resistance in patients of chronic kidney disease (CKD) on maintenance haemodialysis (MHD). Ascorbic Acid 83-96 erythropoietin Homo sapiens 122-136 28792166-10 2017 CONCLUSIONS: Short term i.v ascorbic acid could be a new successful adjuvant in reducing ferritin and erythropoietin resistance and enhancing Hb and TSAT in CKD patients on MHD. Ascorbic Acid 28-41 erythropoietin Homo sapiens 102-116 27170339-0 2016 Oral vitamin C supplementation reduces erythropoietin requirement in hemodialysis patients with functional iron deficiency. Ascorbic Acid 5-14 erythropoietin Homo sapiens 39-53 27170339-13 2016 CONCLUSION: Daily low-dose oral vitamin C supplementation reduced Epo dose requirements in hemodialysis patients with FID. Ascorbic Acid 32-41 erythropoietin Homo sapiens 66-69 27170339-3 2016 High-dose intravenous vitamin C has been shown to decrease the Epo requirement and improve hemoglobin levels in previous studies. Ascorbic Acid 22-31 erythropoietin Homo sapiens 63-66 27170339-4 2016 This study assessed the effect of low-dose oral vitamin C on possible reduction in Epo dose requirements in stable hemodialysis patients with FID. Ascorbic Acid 48-57 erythropoietin Homo sapiens 83-86 17003830-0 2006 Intravenous vitamin C can improve anemia in erythropoietin-hyporesponsive hemodialysis patients. Ascorbic Acid 12-21 erythropoietin Homo sapiens 44-58 26258821-2 2015 It is hypothesized that the decrease of EPO can be attenuated by oxygen free radical scavengers.The aim of the present study was to evaluate whether EPO plasma levels can be influenced by oral application of vitamin C and E before repeated hyperbaric oxygen exposure during diving. Ascorbic Acid 208-217 erythropoietin Homo sapiens 40-43 26258821-2 2015 It is hypothesized that the decrease of EPO can be attenuated by oxygen free radical scavengers.The aim of the present study was to evaluate whether EPO plasma levels can be influenced by oral application of vitamin C and E before repeated hyperbaric oxygen exposure during diving. Ascorbic Acid 208-217 erythropoietin Homo sapiens 149-152 22227182-0 2012 Vitamin C affects the expression of hepcidin and erythropoietin receptor in HepG2 cells. Ascorbic Acid 0-9 erythropoietin Homo sapiens 49-63 22227182-7 2012 EPO downregulated EPOR and vitamin C and upregulated EPOR. Ascorbic Acid 27-36 erythropoietin Homo sapiens 0-3 22227182-11 2012 Moreover, by enhancing EPOR production, vitamin C may correct the downregulating EPOR from EPO, which has additional effect with EPO in treating anemia. Ascorbic Acid 40-49 erythropoietin Homo sapiens 23-26 22227182-11 2012 Moreover, by enhancing EPOR production, vitamin C may correct the downregulating EPOR from EPO, which has additional effect with EPO in treating anemia. Ascorbic Acid 40-49 erythropoietin Homo sapiens 81-84 22690447-0 2012 Is intravenous ascorbic acid an effective and safe option for increasing hemoglobin levels in patients with a hyporesponse to epoetin alfa? Ascorbic Acid 15-28 erythropoietin Homo sapiens 126-133 22690447-3 2012 This article reviews the published data on the effectiveness of intravenous ascorbic acid in increasing the hemoglobin levels of patients with hyporesponse to epoetin alfa, as well as adverse effects of the administration of intravenous ascorbic acid specifically in relation to hyperoxalemia. Ascorbic Acid 76-89 erythropoietin Homo sapiens 159-166 21721439-0 2011 The efficacy of ascorbic acid in suboptimal responsive anemic hemodialysis patients receiving erythropoietin: a meta-analysis. Ascorbic Acid 16-29 erythropoietin Homo sapiens 94-108 21721439-1 2011 BACKGROUND: To determine the impact of adjuvant ascorbic acid therapy on erythropoietin-hyporesponsive, anemic patients undergoing hemodialysis. Ascorbic Acid 48-61 erythropoietin Homo sapiens 73-87 21721439-8 2011 CONCLUSION: Adjuvant ascorbic acid significantly raises hemoglobin levels in patients with erythropoietin hyporesponsiveness undergoing hemodialysis. Ascorbic Acid 21-34 erythropoietin Homo sapiens 91-105 18925528-11 2008 This beneficial profile of effects of ascorbic acid therapy is consistent with improvement of EPO resistance and cost savings in this population. Ascorbic Acid 38-51 erythropoietin Homo sapiens 94-97 18827578-6 2008 A beneficial consequence of parenteral vitamin C on the recombinant human erythropoietin resistance is an additional therapeutic effect, which contributes to the prevention of iron deficiency anaemia in haemodialysis patients. Ascorbic Acid 39-48 erythropoietin Homo sapiens 74-88 18974579-3 2008 We assessed the effect of vitamin C, an antioxidant, on Epo-hyporesponsive anemia in hemodialysis patients with un-explained hyperferritinemia levels. Ascorbic Acid 26-35 erythropoietin Homo sapiens 56-59 18974579-7 2008 In conclusion, hemodialysis patients with refractory anemia and adequate iron stores, vitamin C improved responsiveness to Epo by augmenting iron mobilization and possibly via antioxidant effect. Ascorbic Acid 86-95 erythropoietin Homo sapiens 123-126 18067104-3 2007 EPO and IV-iron might be used more efficiently if two fundamental problems were solved in the management of dialysis patients: better vitamin C status, and avoidance of chronic inflammation. Ascorbic Acid 134-143 erythropoietin Homo sapiens 0-3 18067104-8 2007 Research strategies to improve vitamin C status and to decrease inflammation would lead to better utilization of iron and EPO, and could have parallel benefits for the long-term health of patients on hemodialysis. Ascorbic Acid 31-40 erythropoietin Homo sapiens 122-125 17908648-0 2007 Novel aspects of vitamin C in epoetin response. Ascorbic Acid 17-26 erythropoietin Homo sapiens 30-37 17908648-6 2007 Recent research highlights that vitamin C can potentiate the mobilization of iron from inert tissue stores and facilitates the incorporation of iron into protoporphyrin in HD patients being treated with epoetin. Ascorbic Acid 32-41 erythropoietin Homo sapiens 203-210 17908648-8 2007 This review focuses on the improvement of epoetin response by administration of vitamin C and discusses its clinical implications and potential issues for internal medicine doctors. Ascorbic Acid 80-89 erythropoietin Homo sapiens 42-49 16564942-2 2006 We conducted an open-label prospective study to assess the effect of vitamin C, an antioxidant, on EPO-hyporesponsive anemia in hemodialysis patients with unexplained hyperferritinemia. Ascorbic Acid 69-78 erythropoietin Homo sapiens 99-102 16564942-18 2006 CONCLUSION: In hemodialysis patients with refractory anemia and hyperferritinemia, vitamin C improved responsiveness to EPO, either by augmenting iron mobilization from its tissue stores or through antioxidant effects. Ascorbic Acid 83-92 erythropoietin Homo sapiens 120-123 16109077-2 2005 ascorbic acid (AA) improves anaemia in iron-overloaded, erythropoietin (rEPO) hyporesponsive haemodialysis patients. Ascorbic Acid 0-13 erythropoietin Homo sapiens 56-70 15645737-10 2004 The recombinant erythropoietin dose remained stable for three months in the ascorbic acid, iron, and control groups, respectively. Ascorbic Acid 76-89 erythropoietin Homo sapiens 16-30 15339999-1 2004 Intravenous ascorbic acid (IVAA) medication has been shown to facilitate iron release from inert depots and subsequently circumvent the defective iron utilization in chronic hemodialysis (HD) patients who are treated with recombinant human erythropoietin (rHuEPO). Ascorbic Acid 12-25 erythropoietin Homo sapiens 240-254 15299098-1 2004 BACKGROUND: Intravenous vitamin C supplementation to haemodialysis patients might ameliorate responsiveness to recombinant human erythropoietin (rHuEpo). Ascorbic Acid 24-33 erythropoietin Homo sapiens 129-143 15698458-1 2005 BACKGROUND: There is growing interest to use ascorbic acid as adjuvant therapy for patients with recombinant human erythropoietin-hyporesponsiveness (rHuEpo). Ascorbic Acid 45-58 erythropoietin Homo sapiens 115-129 12830468-1 2003 BACKGROUND: Ascorbic acid supplementation has been recommended to circumvent resistance to erythropoietin, which sometimes occurs in iron-overloaded uremic patients. Ascorbic Acid 12-25 erythropoietin Homo sapiens 91-105 12803508-0 2003 Low dose intravenous ascorbic acid for erythropoietin-hyporesponsive anemia in diabetic hemodialysis patients with iron overload. Ascorbic Acid 21-34 erythropoietin Homo sapiens 39-53 12776276-0 2003 Randomized, crossover study of the effect of vitamin C on EPO response in hemodialysis patients. Ascorbic Acid 45-54 erythropoietin Homo sapiens 58-61 12776276-9 2003 In both groups, vitamin C resulted in a significant increase in hemoglobin levels (P < 0.0001 for both) and a significant decrease in EPO-hemoglobin ratio (P < 0.0001, P = 0.019). Ascorbic Acid 16-25 erythropoietin Homo sapiens 137-140 12776276-13 2003 CONCLUSION: Vitamin C can be used as an effective adjuvant therapy to EPO in hemodialysis patients. Ascorbic Acid 12-21 erythropoietin Homo sapiens 70-73 12803508-2 2003 The effect of intravenous ascorbic acid (IVAA) in HD patients selected on the basis of iron overload and EPO resistance also has been proven. Ascorbic Acid 26-39 erythropoietin Homo sapiens 105-108 10809415-5 2000 In a prospective observational study, SC EPO-treated hospital-based HD patients without conditions known to cause EPO resistance, were managed on intradialytic oral administration of iron and vitamin C. Ascorbic Acid 192-201 erythropoietin Homo sapiens 41-44 11014698-0 2000 Intravenous vitamin C for erythropoietin resistance. Ascorbic Acid 12-21 erythropoietin Homo sapiens 26-40 11276634-0 2000 Ascorbic acid use in hyporesponders to Epoetin alfa. Ascorbic Acid 0-13 erythropoietin Homo sapiens 39-46 11276634-2 2000 ascorbic acid has been used in an effort to mobilize ferritin stores in hyporesponsive HD patients receiving Epoetin alfa. Ascorbic Acid 0-13 erythropoietin Homo sapiens 109-116 11276634-6 2000 Ascorbic acid"s effect on hemosiderin deposits may be another possible mechanism to the increased Epoetin alfa response observed in some HD patients (Hemosiderin is a pathologic deposition of iron in tissues including the spleen, small intestine, and bone marrow). Ascorbic Acid 0-13 erythropoietin Homo sapiens 98-105 11276634-13 2000 ascorbic acid should be considered as a possible adjuvant to therapy in patients who are "iron-overloaded" and hyporesponsive to Epoetin alfa. Ascorbic Acid 0-13 erythropoietin Homo sapiens 129-136 11276634-21 2000 ascorbic acid therapy in iron overloaded HD patients receiving Epoetin alfa. Ascorbic Acid 0-13 erythropoietin Homo sapiens 63-70 11952508-0 2002 Intravenous ascorbic acid administration for erythropoietin-hyporesponsive anemia in iron loaded hemodialysis patients. Ascorbic Acid 12-25 erythropoietin Homo sapiens 45-59 11952508-1 2002 Intravenous ascorbic acid administration (IVAA) could override recombinant human erythropoietin (rHuEPO) resistance in hemodialysis patients with iron overload. Ascorbic Acid 12-25 erythropoietin Homo sapiens 81-95 11509682-0 2001 Erythropoietin and iron: the role of ascorbic acid. Ascorbic Acid 37-50 erythropoietin Homo sapiens 0-14 11590253-8 2001 Deficiencies in vitamin B(12), folic acid and potentially vitamin C can all reduce the efficacy of treatment with rh-Epo. Ascorbic Acid 58-67 erythropoietin Homo sapiens 117-120 9829492-0 1998 A parallel, comparative study of intravenous iron versus intravenous ascorbic acid for erythropoietin-hyporesponsive anaemia in haemodialysis patients with iron overload. Ascorbic Acid 69-82 erythropoietin Homo sapiens 87-101 10354297-0 1999 Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia. Ascorbic Acid 12-25 erythropoietin Homo sapiens 65-79 9829492-14 1998 In contrast, mean haematocrit significantly increased from 25.8+/-0.5 to 30.6+/-0.6% with a concomitant reduction of 20% in erythropoietin dose after 8 weeks of ascorbate therapy. Ascorbic Acid 161-170 erythropoietin Homo sapiens 124-138 9829492-19 1998 Our study draws attention to a potential adjuvant therapy, intravenous ascorbic acid, to treat erythropoietin-hyporesponsive anaemia in iron-overloaded patients. Ascorbic Acid 71-84 erythropoietin Homo sapiens 95-109